Drug Shortage Report for TAKHZYRO
Report ID | 151175 |
Drug Identification Number | 02480948 |
Brand name | TAKHZYRO |
Common or Proper name | Lanadelumab Injection |
Company Name | TAKEDA CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | LANADELUMAB |
Strength(s) | 300MG |
Dosage form(s) | SOLUTION |
Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
Packaging size | 2 mL Vial |
ATC code | B06AC |
ATC description | |
Reason for shortage | Delay in shipping of the drug. |
Anticipated start date | 2021-12-15 |
Actual start date | 2021-12-15 |
Estimated end date | 2022-01-14 |
Actual end date | 2022-01-12 |
Shortage status | Resolved |
Updated date | 2022-01-13 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 22 ADELAIDE STREET WEST TORONTO, ONTARIO CANADA M5H 4E3 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v8 | 2022-01-13 | French | Compare |
v7 | 2022-01-13 | English | Compare |
v6 | 2022-01-06 | French | Compare |
v5 | 2022-01-06 | English | Compare |
v4 | 2021-12-16 | English | Compare |
v3 | 2021-12-15 | French | Compare |
v2 | 2021-12-15 | English | Compare |
v1 | 2021-12-15 | English | Compare |
Showing 1 to 8 of 8